Four of the flavouring substances are classified into structural class I, and three are classified into structural class II.
Five of the seven flavouring substances in this group have been reported to occur naturally in a wide range of food items.
In its evaluation, the Panel as a default used the Maximised Survey-derived Daily Intake (MSDI) approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the Panel examined the information provided by the European Flavour Industry on the use levels in various foods, it appeared obvious that the MSDI approach in a number of cases would grossly underestimate the intake by regular consumers of products flavoured at the use level reported by the Industry, especially in those cases where the annual production values were reported to be small. In consequence, the Panel had reservations about the data on use and use levels provided and the intake estimates obtained by the MSDI approach.
In the absence of more precise information that would enable the Panel to make a more realistic estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake (mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding threshold of concern, the Panel decided not to carry out a formal safety assessment using the Procedure. In these cases the Panel requires more precise data on use and use levels.
According to the default MSDI approach, the seven flavouring substances in this group have estimated intakes in Europe from 0.0012 to 3.0 microgram/capita/day, which are below the threshold of concern value for both structural class I (1800 microgram/person/day) and structural class II (540 microgram/person/day) substances.
Genotoxicity data are available only for a limited number of the substances, and the genotoxicity could not be assessed adequately. However, the data available do not preclude evaluation of the flavouring substances in the present group using the Procedure.
The seven flavouring substances are expected to be metabolised to innocuous products.
It was noted that where toxicity data were available they were consistent with the conclusions in the present FGE using the Procedure.
On the basis of the default MSDI approach the Panel concluded that the seven flavouring substances would not give rise to safety concerns at the estimated levels of intake arising from their use as flavouring substances.
Substances which are listed in the Register are to be evaluated according to the evaluation programme laid down in Commission Regulation (EC) No 1565 (EC, 2000 , which is broadly based on the Opinion of the Scientific Committee on Food (SCF, 1999) . For the submission of data by the manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 2002b .
The Flavouring Group Evaluation (FGE) is revised to include a substance for which data were submitted after the deadline as laid down in Commission Regulation (EC) No 622/2002 (EC, 2002b and to take into account additional information that has been made available since the previous Opinion on this FGE.
The revision also includes newly notified substances belonging to the chemical group evaluated in this FGE.
After the completion of the evaluation programme the positive list of flavouring substances for use in or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996) .
The present revision of FGE.11, FGE.11Rev1, includes the assessment of two additional candidate substances . No toxicity or metabolism date were available for these two substances. Otherwise no additional information was made available since FGE.11 was published.
One flavouring substance, pentan-2, ) was deleted from the Register of flavouring substances as it is considered genotoxic in vitro and in vivo. Accordingly, its use as chemically defined flavouring substance is toxicologically not acceptable.
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TERMS OF REFERENCE
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring substances in the Register prior to their authorisation and inclusion in a positive list according to Commission Regulation (EC) No 1565 (EC, 2000 . In addition, the Commission requested EFSA to evaluate newly notified flavouring substances, where possible, before finalising the evaluation programme.
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Flavouring Group Evaluation 11, Revision 1 (FGE.11Rev1) Aliphatic dialcohols, diketones, and hydroxyketones from chemical group 10 ASSESSMENT 1. Presentation of the Substances in the Flavouring Group Evaluation 11, Revision 1
Description
The present Flavouring Group Evaluation 11, Revision 1 (FGE.11Rev1), using the Procedure as referred to in the Commission Regulation (EC) No 1565/2000 (the Procedure -shown in schematic form in Annex I), deals with six alpha-diketones or their corresponding alcohols or ketal and one beta-hydroxy ketone. These seven flavouring substances (candidate substances) belong to chemical group 10 of Annex I of Regulation (EC) No 1565 (EC, 2000 .
One flavouring substance, pentan-2, ]) was deleted from the Register of flavouring substances as it is considered genotoxic in vitro and in vivo.
The seven candidate substances under consideration in the present evaluation are listed in Table 1 and 2a, as well as their chemical Register names, FLAVIS-(FL-), Chemical Abstract Service-(CAS-), Council of Europe-(CoE-) and Flavor and Extract Manufacturers Association-(FEMA-) numbers, structures and specifications. This group of candidate substances includes six alphadiketones or their corresponding alcohols or ketal 07.071, 07.152, 07.167, 07.238 and 07.260] , and one beta-hydroxy ketone (tertiary alcohol) ].
The hydrolysis products of the candidate ketal are listed in Table 2b .
The seven candidate substances are closely related structurally to 13 aliphatic acyclic alphadiketones and related alpha-hydroxyketones (supporting substances) evaluated at the 51 st meeting of the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) in the group "Aliphatic acyclic and alicyclic alpha-diketones and related alpha-hydroxyketones" (JECFA, 1999a) . The names and structures of the 13 supporting substances are listed in Table 3 , together with their evaluation status.
Stereoisomers
It is recognised that geometrical and optical isomers of substances may have different properties. Their flavour may be different, they may have different chemical properties resulting in possible variability in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be provided on the configuration of the flavouring substance, i.e. whether it is one of the geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of purity will be considered in order to determine whether the safety evaluation carried out for candidate substances for which stereoisomers may exist can be applied to the material of commerce.
Flavouring substances with different configurations should have individual chemical names and codes (CAS number, FLAVIS number, etc.).
One of the seven candidate substances possesses two chiral centres and two substances possesses one chiral centre . In all of these cases the substances have been presented without any indication whether the commercial flavouring substance was dominated by one of the optical isomers. One of the substances ] is a mixture of four isomers (three positions isomers, one of these can exists as two stereoisomers) and the composition of mixture is not specified.
Natural Occurrence in Food
Five of the seven candidate substances have been reported to occur in fruits, fruit juice, vegetables, bread, cheese, cocoa, wine, drinks, beer, tea, and coffee. Quantitative data on the natural occurrence in food have been reported for four of these substances (TNO, 2000; EFFA, 2004x ; Flavour Industry, 2005b) .
These reports are:
• Butane-2,3-diol [FL-no: 02.133]: 0.006 mg/kg in fish (lean), up to 90 mg/kg in cheddar cheese, up to 2.3 mg/kg in raspberry, up to 850 mg/kg in vinegar, 1.9 mg/kg in sherry, and up to 2900 mg/kg in various types of wine. • 3,3-Diethoxybutan-2-one ]: up to 0.1 mg/kg in cognac and weinbrand.
• 4-Hydroxy-4-methylpentan-2-one ]: up to 0.07 mg/kg in roasted chicken.
According to TNO two of the substances, 3-hydroxy-2-octanone [FL-no: 07.238] and 1-or 3hydroxy-5-methyl-2-or 3-hexanone [FL-no: 07.260] have not been reported to occur naturally in any food items (TNO, 2000) .
Specifications
Purity criteria for the seven candidate substances have been provided by the Flavour Industry (EFFA, 2003e; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b ) (see Table 1 ).
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565 (EC, 2000 , the information on boiling point is missing for ]. Otherwise the specifications are adequate for all seven candidate substances (see Table 1 ), except that information on stereoisomerism/composition of mixture is needed for four substances 07.167, 07.238, 07 .260] (see section 1.2 and Table 1 ).
Intake Data
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to calculate the "Maximised Survey-derived Daily Intake" (MSDI) by assuming that the production figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU population are consumers (SCF, 1999) .
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability of intake estimates on the basis of the MSDI approach is difficult to assess.
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the basis of this MSDI approach, in some cases the regular consumption of products flavoured at use levels reported by the Flavour Industry in the submissions would result in much higher intakes. In such cases, the human exposure thresholds below which exposures are not considered to present a safety concern might be exceeded.
Considering that the MSDI model may underestimate the intake of flavouring substances by certain groups of consumers, the SCF recommended also taking into account the results of other intake assessments (SCF, 1999) .
One of the alternatives is the "Theoretical Added Maximum Daily Intake" (TAMDI) approach, which is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable beverages and foods in general, with exceptional levels for particular foods. This method is regarded as a conservative estimate of the actual intake in most consumers because it is based on the assumption that the consumer regularly eats and drinks several food products containing the same flavouring substance at the upper use level.
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use levels of the flavouring substances. This modified TAMDI approach (mTAMDI) is less conservative (e.g., it may underestimate the intake of consumers being loyal to products flavoured at the maximum use levels reported) (EC, 2000) . However, it is considered as a suitable tool to screen and prioritise the flavouring substances according to the need for refined intake data (EFSA, 2004a).
Estimated Daily per Capita Intake (MSDI Approach)
The Maximised Survey-derived Daily Intake (MSDI (SCF, 1999)) data are derived from surveys on annual production volumes in Europe. These surveys were conducted in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers reported the total amount of each flavouring substance incorporated into food sold in the EU during the previous year (IOFI, 1995) . The intake approach does not consider the possible natural occurrence in food.
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is consumed by 10 % of the EU population 2 (Eurostat, 1998) . This is derived for candidate substances from estimates of annual volume of production provided by Industry and incorporates a correction factor of 0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999) .
In the present Flavouring Group Evaluation, Revision 1 (FGE.11Rev1) the total annual volume of production of the seven candidate substances for use as flavouring substances in Europe has been reported to be approximately 51 kg (EFFA, 2003f; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b) . 25 kg is accounted for by butane-2,3-diol [FL-no: 02.133] and 19 kg is accounted for by 1-or 3-hydroxy-5-methyl-2-or 3-hexanone ]. For the 13 supporting substances the total annual volume of production has been rapported by JECFA to be approximately 38000 kg. .052] accounts for 18000 kg and 3-hydroxybutan-2-one [FL-no: 07.051] accounts for 19000 kg (JECFA, 2000a) .
On the basis of the annual volumes of production reported for the seven candidate substances, the daily per capita intakes for each of these flavourings have been estimated (Table 2a ). The estimated daily per capita intake of butane-2,3-diol [FL-no: 02.133] and of 1-or 3-hydroxy-5-methyl-2 or 3hexanone [FL-no: 07.260] from use as a flavouring substance is 3.0 microgram and 2.3 microgram, respectively. The daily per capita intakes for each of the remaining substances are less than 0.088 microgram (Table 2a ).
Intake Estimated on the Basis of the Modified TAMDI (mTAMDI)
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is based on the approach used by SCF up to 1995 (SCF, 1995 .
The assumption is that a person may consume a certain amount of flavourable foods and beverages per day.
For the present evaluation of the seven candidate substances, information on food categories and normal and maximum use levels 3,4,5 were submitted by the Flavour Industry (EFFA, 2003e; EFFA, 2003f; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b; EFFA, 2007a) .
The seven candidate substances are used in flavoured food products divided into the food categories, outlined in Annex III of the Commission Regulation (EC) No 1565 (EC, 2000 , as shown in Table 3 .1. For the present calculation of mTAMDI, the reported normal use levels were used. In the case where different use levels were reported for different food categories the highest reported normal use level was used.
According to the Flavour Industry, the normal use levels for the seven candidate substances are in the range of 1 -20 mg/kg food, and the maximum use levels are in the range of 5 -100 mg/kg (EFFA, 2003e; EFFA, 2003f; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b , EFFA, 02007a) (See Table II .1.2, Appendix II).
The mTAMDI values for the four candidate substances from structural class I (see Section 5) range from 1600 to 3900 microgram/person/day. For the three candidate substances from structural class II the mTAMDI values range from 1500 to 1600 microgram/person/day.
For detailed information on use levels and intake estimations based on the mTAMDI approach, see Section 6 and Annex II.
3 "Normal use" is defined as the average of reported usages and "maximum use" is defined as the 95 th percentile of reported usages (EFFA, 2002i) . 4 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e) . 5 The use levels from food category 5 "Confectionery" have been inserted as default values for food category 14.2 "Alcoholic beverages" for substances for which no data have been given for food category 14.2 (EFFA, 2007a) .
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Absorption, Distribution, Metabolism and Elimination
The seven candidate substances, alpha-diketones and a related ketal, hydroxyketones and diols, are expected to be absorbed from the gastrointestinal tract. The metabolic fate of acyclic aliphatic diketones depends primarily on the position of the carbonyl function and the chain length. Aliphatic acyclic diketones and alpha-hydroxyketones which contain a carbonyl function at the 2-position (i.e. a methyl ketone) may undergo alpha-hydroxylation and subsequent oxidation of the terminal methyl group to eventually yield corresponding ketocarboxylic acids. The ketoacids are intermediary metabolites (e.g. alpha-ketoacids), which may undergo oxidative decarboxylation to yield carbon dioxide and an aliphatic carboxylic acid. The acid may be completely metabolised in the fatty acid pathway and citric acid cycle.
Alternatively, the methyl-substituted diketones may be successively reduced to the corresponding hydroxyketones and diols, which are excreted in the urine as glucuronic acid conjugates. This pathway is favoured at elevated in vivo concentrations, especially for longer chain length ketones. If the carbonyl function is located elsewhere on the chain, reduction is the predominant detoxification pathway. Alpha-hydroxyketones or their diol metabolites may be excreted as glucuronic acid conjugates.
A more detailed discussion on the metabolism of these alpha-diketones, a related ketal, hydroxyketones and diols follows in Annex III.
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Application of the Procedure for the Safety Evaluation of Flavouring Substances
In FGE.11, one of the six candidate substances, pentan-2,4-dione was concluded to have genotoxic potential in vitro and in vivo and accordingly, based on the genotoxicity data available, the Procedure was not applied for this substance.
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach.
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. In these cases the Panel requires more precise data on use and use levels. For comparison of the intake estimations based on the MSDI approach and the mTAMDI approach, see Section 6.
For the safety evaluation of the seven candidate substances from chemical group 10 the Procedure was applied. The stepwise evaluations of the seven substances are summarised in Table 2a .
Step 1
Four of the candidate substances [FL-no: 02.133, 07.165, 07.167 and 07.238] are classified in structural class I according to the decision tree approach presented by Cramer et al. (Cramer et al., 1978) . The remaining three substances are in structural class II [FL-no: 07.071, 07.152 and 07.260].
Step 2 At the estimated levels of intake, the seven candidate substances would not be expected to saturate metabolic detoxification pathways. They are considered to be metabolised to innocuous products. The evaluation of these seven candidate substances, therefore, proceeds via the A-side of the Procedure scheme (Annex I).
Step A3
The estimated levels of intake for the four candidate substances classified in structural class I are in the range of 0.0012 -3.0 microgram/capita/day, which are below the human intake threshold of concern for structural class I (1800 microgram/person/day). The intakes of the three class II candidate substances are 0.0012 microgram/capita/day for [FL-no: 07.071], 0.088 microgram/capita/day for [FL-no: 07.152] and 2.3 microgram/capita/day for [FL-no: 07.260], which also are below the human intake threshold for that class (540 microgram/person/day) (Table  2a ).
Based on the results of the safety evaluation sequence of the Procedure, these seven candidate substances proceeding via the A-side of the Procedure scheme do not pose a safety concern when used as flavouring substances at the estimated levels of intake, based on MSDI approach.
Comparison of the Intake Estimations based on the MSDI Approach and the mTAMDI Approach
The estimated intakes for the four candidate substances in structural class I based on the mTAMDI approach range from 1600 to 3900 microgram/person/day. For one of the substances the mTAMDI value is above the threshold of concern for structural class I of 1800 microgram/person/day. For comparison of the intake estimate based on the MSDI approach and mTAMDI approach, see Table  6 .1.
The estimated intakes for the three candidate substances assigned to structural class II based on the mTAMDI range from 1500 to 1600 microgram/person/day, which is above the threshold of concern for structural class II substances of 540 microgram/person/day. For comparison of the MSDI and mTAMDI values, see Table 6 .1.
For four of the seven candidate substances further information is required. This would include more reliable intake data and then, if required, additional toxicological data. 
Structural class
Threshold of concern (µg/person/day) 
Considerations of Combined Intakes From Use as Flavouring Substances
Because of structural similarities of candidate and supporting substances, it can be anticipated that many of the flavourings are metabolised through the same metabolic pathways and that the metabolites may affect the same target organs. Further, in case of combined exposure to structurally related flavourings, the pathways could be overloaded. Therefore, combined intake should be considered. As flavourings not included in this FGE may also be metabolised through the same pathways, the combined intake estimates presented here are only preliminary. Currently, the combined intake estimates are only based on MSDI exposure estimates, although it is recognised that this may lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed.
The beta-hydroxyketone, 4-hydroxy-4-methylpentan-2-one [FL-no: 07.165], is not considered for combined intake together with the six alpha-diketones in FGE.11Rev1 for the following reason: The distance between the secondary alcohol groups is anticipated to be essential for the potential toxicological effects as demonstrated by gamma-diketones being neurotoxic. It should be remarked that the beta-hydroxyketone, 4-hydroxy-4-methylpentan-2-one [FL-no: 07.165], (being a tertiary alcohol) is not a precursor for a beta-diketone.
The estimated combined daily per capita intake of structurally related flavourings is estimated by summing the MSDI for individual substances.
On the basis of the reported annual production volumes in Europe (EFFA, 2003e; EFFA, 2003f; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b ) the estimated combined daily per capita intake as flavourings of the six candidate substances, which are alpha-diketones or precursors, assigned to structural class I or II is 5.4 microgram. This combined intake does not exceed the thresholds of concern for substances belonging to structural class I of 1800 or II of 540 microgram/person/day, respectively.
The six candidate substances [FL-no: 02.133, 07.071, 07.152, 07.167, 07.238 and 07.260] are structurally related to 13 supporting substances, which all are alpha-diketones or precursors evaluated by JEFCA at its 51 st meeting. For 12 of these supporting substances European annual Flavouring Group Evaluation 11, Revision 1 (FGE.11Rev1) Aliphatic dialcohols, diketones, and hydroxyketones from chemical group 10 production volumes have been provided by Flavour Industry. The 12 supporting substances are all assigned to structural class II. The total estimated combined daily intake of the candidate and supporting substances (in Europe) is approximately 4600 microgram/capita, which would exceed the threshold of concern for structural class II (540 microgram/person/day).
However, based on the high capacity of enzymes in the metabolic pathways, it is anticipated that the combined intake of candidate substances (5.4 microgram/capita/day) and supporting substances (4600 microgram/capita/day) would be metabolised efficiently and would not saturate these metabolic pathways. Further, based on the data available, two supporting substances (diacetyl [FLno: 07.052] 2200 microgram/capita/day and 3-hydroxybutan-2-one [FL-no: 07.051] 2300 microgram/capita/day) out of the total of 19 candidates and supporting substances provide 95 % of the contribution. These are present in the body as endogenous compounds (Kawano, 1959; Gabriel et al., 1972) and they would not be expected to give rise to perturbations outside the physiological range (JECFA, 1999a) . Therefore, at the level of exposure, based on the MSDI approach, the total combined intake as flavouring substances of the candidate and supporting substances would not be expected to be of safety concern.
8. Toxicity Oral LD 50 values in rats and mice are in the range from 600 to 9000 mg/kg body weight (bw).
The acute toxicity data are summarised in Annex IV, For one of the candidate substances, 4-hydroxy-4-methylpentan-2-one [FL-no: 07.165], in vitro studies have been reported; with negative results obtained in bacterial gene mutation assays with and without metabolic activation as well as in a chromosomal aberration assay in rat liver cells in vitro. For a second candidate substance, butane-2,3-diol [FL-no: 02.133], there is only one Ames test reported to be negative, but the validity of the study cannot be evaluated. For pentan-2,4-dione, both in vitro and in vivo studies are available. In the various in vitro studies reported (reverse mutation assays (Ames tests), microbial DNA repair tests and tests on primary DNA damage, gene mutation and chromosomal aberrations) negative results were observed in three Ames tests with six tester strains of Salmonella typhimurium with and without metabolic activation and in a chromosomal aberrations test in the presence of metabolic activation. Positive results were found in two of the Ames tests with S. typhimurium strain TA104 with or without metabolic activation, however, the validity of these results cannot be evaluated since cytotoxicity data have not been reported. Positive results were also observed in the chromosomal aberrations test in the absence of metabolic activation. For the three tests on microbial DNA repair both positive and negative results have been reported. However, they followed unusual study protocols and experimental details are insufficiently reported. Thus the results are of limited validity. In two in vivo micronucleus studies, which were performed in compliance with GLP and in accordance with OECD guideline 474 in mice, significant increases in micronucleated polychromatic erythrocytes were observed in peripheral blood as well as in bone marrow. Test concentrations used were high and close to the LD50 determined in the same test system, however, there was no decrease in the ratio of PCE/NCE, on the contrary an increase was reported. The results were clearly positive in both studies which are considered as valid. The same test protocol was used in an in vivo micronucleus study in rats. However, test concentrations had to be reduced due to excessive mortality. Under these conditions, negative results were observed in the micronucleus test in rats. There were no significant changes in the proportion of PCE. Therefore, the validity of the results of this study is limited.
Genotoxicity studies were also performed with five supporting substances:
For Pentan-2,4-dione is genotoxic in vitro and in vivo. In in vitro studies considered as valid, it induced chromosomal aberrations without metabolic activation and sister chromatid exchanges with and Flavouring Group Evaluation 11, Revision 1 (FGE.11Rev1) Aliphatic dialcohols, diketones, and hydroxyketones from chemical group 10 without metabolic activation while no gene mutations were observed in bacteria and mammalian cells. In vivo, pentan-2,4-dione induced micronuclei in mice peripheral blood and bone marrow. It should be noted that only pentan-2,4-dione exhibits the structural feature of a methylene group which is activated due to its position between two carbonyl groups.
Mutagenicity data are available for five of the 13 supporting substances, giving mainly negative results. There is indication that diacetyl [FL-no: 07.052] has a weak genotoxic activity in vitro. However, diacetyl is reported to be endogenous in humans and is reported to be rapidly reduced to acetoin and further to butan-2,3-diol, for which there are no indication of mutagenicity.
Conclusion on genotoxicity
The genotoxicity data available on candidate and supporting substances do not preclude evaluation of the candidate substances in the present group using the Procedure.
Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV .5.
Conclusions
The Four of the candidate substances are classified in structural class I and three are classified in structural class II.
Five of the seven candidate substances in the present group have been reported to occur naturally in a wide range of food items.
According to the default MSDI approach, the seven candidate substances have European daily per capita intakes ranging from 0.0012 to 3.0 microgram, which are below the thresholds of concern for structural class I and II (1800 and 540 microgram/person/day, respectively).
On the basis of the reported annual production in Europe (MSDI apprach) the combined intake of the six candidate substances being alpha-diketones or precursors, assigned to structural class I or II, is 5.4 microgram. This combined intake does not exceed the threshold of concern for a substance belonging to structural class II of 540 microgram/person/day. The supporting substances are all assigned to structural class II. The total combined estimated level of intake of candidate and supporting substances is approximately 4600 microgram/capita, which would exceed the threshold of concern for structural class II (540 microgram/person/day). However, based on information on efficient metabolism and on presence in the body as endogenous compounds, there are no safety concerns from the combined intake of the candidate and supporting substances.
Genotoxicity data are available only for a limited number of substances, and the genotoxicity could not be assessed adequately. However, the data available do not preclude evaluation of the candidate substances using the Procedure.
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It is considered that on the basis of the default MSDI approach the seven candidate substances [FLno: 02.133, 07.071, 07.152, 07.165, 07.167, 07 .238 and 07.260] would not give rise to safety concerns at the estimated levels of intake arising from their use as flavouring substances.
When the estimated intakes were based on the mTAMDI they ranged from 1600 to 3900 microgram/person/day for the four candidate substances from structural class I. For one of these candidate substances .133] the estimated intake is above the threshold of concern of 1800 microgram/person/day. For the three candidate substances [FL-no: 07.071, 07.152 and 07.260] which are assigned to structural class II, the estimated intake based on the mTAMDI range from 1500 to 1600 microgram/person/day which is above the threshold of concern for structural class II of 540 microgram/person/day. The three candidate substances 07.167, 07.238] , which have mTAMDI intake estimates below the threshold of concern for structural class I are also expected to be metabolised to innocuous products.
Thus, for four of the candidate substances [FL-no: 02.133, 07.071, 07.152 and 07.260] the intakes, estimated on the basis of the mTAMDI, exceed the threshold for the structural class to which the flavouring substances have been assigned. Therefore, more reliable exposure data are required. On the basis of such additional data, the substances, should be reconsidered along the steps of the Procedure. Following this procedure additional toxicological data might become necessary.
In order to determine whether the conclusion for the candidate substances can be applied to the material of commerce, it is necessary to consider the available specifications:
Adequate specifications including complete purity criteria and identity tests for the materials of commerce have been provided for the seven flavouring substances [FL-no: would present no safety concern at the levels of intake estimated on the basis of the MSDI approach.
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The EFSA Journal (2008) 493, 21-48 2) Thresholds of concern: Class I = 1800, Class II = 540, Class III = 90 µg/person/day.
3) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
4)
No safety concern based on intake calculated by the MSDI approach of the named compound. 5) Data must be available on the substance or closely related substances to perform a safety evaluation. 6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism.
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce.
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Category 1 a)
No safety concern b) No evaluation
At the 46 th JECFA meeting (JECFA, 1997a), the Committee concluded that ethanol posed no safety concern at its current level of intake when ethyl esters are used as flavouring agents.
Diacetyl 408
O O No safety concern c) Category A d) Class II A3: Intake above threshold, A4: Endogenous 1) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4): Not acceptable due to evidence of toxicity.
2) No safety concern at estimated levels of intake.
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs.
4) Threshold of concern:
Class I = 1800, Class II = 540, Class III = 90 µg/person/day. 5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. a) (SCF, 1995) . b) (JECFA, 1997a) . c) (JECFA, 2000a) . d) (CoE, 1992) .
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The EFSA Journal (2008) 493, 24-48 No safety concern a) Category ND No safety concern a) JECFA evaluated 3hydroxy-2-pentanone (CASrn as in Register 
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2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity.
3) No safety concern at estimated levels of intake.
4) Category A:
Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. a) (JECFA, 2000a) . b) (CoE, 1992) .
The EFSA Journal (2008) 493, 26-48
ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION
The approach for a safety evaluation of chemically defined flavouring substances as referred to in Commission Regulation (EC) No 1565 (EC, 2000 , named the "Procedure", is shown in schematic form in Figure I.1 . The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 2 December 1999 (SCF, 1999) , which is derived from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food Additives at its 44 th , 46 th and 49 th meetings (JECFA, 1995; JECFA, 1996a; JECFA, 1997a; JECFA, 1999b) .
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-activity relationships, metabolism and, when needed, toxicity. One of the key elements in the procedure is the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a safety concern.
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer et al., 1978) . The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, respectively, are derived from a large database containing data on subchronic and chronic animal studies (JECFA, 1996a).
In
Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps address the following questions:
• can the flavourings be predicted to be metabolised to innocuous products 6 (Step 2)?
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)?
• are the flavourings or their metabolites endogenous 7 (Step A4)?
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)?
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), toxicological background information available for compounds structurally related to the candidate substances is considered (supporting substances), in order to assure that these data are consistent with the results obtained after application of the Procedure.
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, the right is reserved to use alternative approaches if data on specific flavourings warranted such actions.
6 "Innocuous metabolic products": Products that are known or readily predicted to be harmless to humans at the estimated intakes of the flavouring agent" (JECFA, 1997a) .
7 "Endogenous substances": Intermediary metabolites normally present in human tissues and fluids, whether free or conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included (JECFA, 1997a) .
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Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
Do the conditions of use result in an intake greater than the threshold of concern for the structural class?
Data must be available on the substance or closely related substances to perform a safety evaluation Does a NOAEL exist for the substance which provides an adequate margin of safety under conditions of intended use, or does a NOAEL exist for structurally related substances which is high enough to accommodate any perceived difference in toxicity between the substance and the related substances?
Does a NOAEL exist for the substance which provides an adequate margin of safety under conditions of intended use, or does a NOAEL exist for structurally related substances which is high enough to accommodate any perceived difference in toxicity between the substance and the related substances?
Substance would not be expected to be of safety concern Is the substance or are its metabolites endogenous?
Additional data required
Step 1.
Step 2.
Step A3.
Step A4.
Step A5.
Step B3.
Step B4. 
Yes No
Yes
II.1 Normal and Maximum Use Levels
For each of the 18 Food categories (Table II. 1.1) in which the candidate substances are used, Flavour Industry reports a "normal use level" and a "maximum use level" (EC, 2000) . According to the Industry the "normal use" is defined as the average of reported usages and "maximum use" is defined as the 95 th percentile of reported usages (EFFA, 2002i) . The normal and maximum use levels in different food categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). The "normal and maximum use levels" are provided by Industry (EFFA, 2003e; EFFA, 2003f; Flavour Industry, 2005b; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b; EFFA, 2007a) .for all the candidate substances in the present flavouring group (Table II. 1.2). 
II.2 mTAMDI Calculations
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is based on the approach used by SCF up to 1995 (SCF, 1995 . The assumption is that a person may consume the amount of flavourable foods and beverages listed in Table II .2.1. These consumption estimates are then multiplied by the reported use levels in the different food categories and summed up.
The present mTAMDI calculations are based on the normal use levels reported by Industry. The seven food categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in Commission Regulation (EC) No 1565/2000 (EC, 2000) and reported by the Flavour Industry in the following way (see Table II .2.2):
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000)
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 (EC, 2000) • Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000) • Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000) • Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000) • Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000) • Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. The mTAMDI values (see Table II .2.3) are presented for each of the seven flavouring substances in the present flavouring group, for which Industry has provided use and use levels (EFFA, 2003e; EFFA, 2003f; EFFA, 2004x; Flavour Industry, 2005a; Flavour Industry, 2005b; EFFA, 2007a) . The mTAMDI values are only given for highest reported normal use levels (see Table II .2.3 and II.2.4). 
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III.1. Absorption, Distribution, Metabolism and Elimination
The candidate substances and supporting substances aliphatic acyclic alpha-diketones participate in a keto-enol equilibrium with the corresponding ketoenol (see Figure III .1). The keto form predominates (Gordon & Ford, 1972) .
In rats and mice, orally administered acetoin (3-hydroxybutan-2-one [FL-no: 07.051]) is rapidly absorbed from the gastrointestinal tract (Gabriel et al., 1972) . Upon injection of acetoin-2,3-14 C to albino rats, 14 CO 2 appears in the expired air. The average 12-20 hours 14 CO 2 production from acetoin-2,3-14 C was found to be 15 % after intraperitoneal (i.p.) administration (12h) and 47.7 % after intracardial administration (20h) (Gabriel et al., 1972) . 
III.2. Biotransformation
III.2.1. Hydrolysis
In general, esters are hydrolysed to their corresponding alcohol and carboxylic acid. Classes of enzymes recognised as carboxylesterases or esterases, the most important of which are the Besterases, catalyse hydrolysis. Acetyl esters are the preferred substrates of C-esterases (Heymann, 1980) . In mammals these enzymes occur in most tissues throughout the body (Anders, 1989; Heymann, 1980) but predominate in hepatocytes (Heymann, 1980) . As an example, it is expected that the supporting chemicals, 2-acetoxy-3-butanone and butanon-3-one-2-yl butanoate, are metabolised in humans to acetic acid and butanoic acid, respectively, and acetoin.
Acetals and ketals are readily hydrolysed after ingestion under the acidic conditions in the stomach to their corresponding alcohol and aldehyde or ketone, respectively, prior to absorption.
III.2.2. Metabolism of Aliphatic Acyclic Diketones
The metabolic fate of acyclic aliphatic diketones depends primarily on the position of the carbonyl function and the chain length. Aliphatic acyclic diketones and alpha-hydroxyketones, which contain a carbonyl function at the 2-position (i.e. a methyl ketone) may undergo alphahydroxylation and subsequent oxidation of the terminal methyl group to eventually yield corresponding ketocarboxylic acids. The ketoacids are intermediary metabolites (e.g. alphaketoacids), which may undergo oxidative decarboxylation to yield carbon dioxide and an aliphatic carboxylic acid. The acid may be completely metabolised in the fatty acid pathway and citric acid cycle (see Figure III .1). Beta-keto acids and derivatives readily undergo decarboxylation. Along with alpha-keto and alpha-hydroxyacids, they yield breakdown products, which are incorporated into normal biochemical pathways (EFSA, 2005b) .
Alternately, the methyl-substituted diketones may be successively reduced to the corresponding hydroxyketones and diols, which are excreted in the urine as glucuronic acid conjugates. This pathway is favoured at elevated in vivo concentrations, especially for longer chain length ketones. If the carbonyl function is located elsewhere on the chain, reduction is the predominant detoxification pathway.
alpha-Hydroxyketones or their diol metabolites may be excreted as glucuronic acid conjugates (JECFA, 1999a) .
Acetoin is metabolised primarily via oxidation at low concentrations in vivo and by reduction to 2,3-butanediol (butane-2,3-diol) at high concentrations. It is estimated that the rat liver is capable of oxidising 86 microgram (1 micromole) acetoin/g liver per day (Gabriel et al., 1972) .
Oxidation of the terminal methyl group may form an alpha-ketoacid, which undergoes cleavage to yield CO 2 and a carboxylic acid fragment.
A total dose of 78 g of acetoin was administered to a dog over a two-month period. The doses were given orally in a 3 to 4 percent solution and subcutaneously in a 20 percent solution.
Urine was collected under toluene from the beginning of the dosing period through 40 hours after the last treatment. Butane-2,3-diol was identified as the major urinary excretion product, ranging from 5 to 25 percent of the dose. The remainder of the dose was completely metabolised (Westerfeld & Berg, 1943) .
In liver preparations obtained from rats and rabbits, greater than 95 % of the radioactivity of 2,3-14 C-acetoin was detected as a mixture of stereoisomers of butane-2,3-diol (Gabriel et al., 1971) . Although reduction of diacetyl and acetoin have been observed in animals in vivo and in animal tissue preparation in vitro at high concentrations, it appears that oxidation of diacetyl is a major endogenous metabolic pathway.
Reduction of ketones is mediated by alcohol dehydrogenase and NADPH dependent cytosolic carbonyl reductases (Bosron & Li, 1980) . Reduction of acetoin and diacetyl is catalysed by the substrate-specific enzymes diacetyl reductase and acetoin reductase, respectively. In rat liver mince, diacetyl, acetoin and butane-2,3-diol are interconvertible (Gabriel et al., 1972) .
In male Wistar albino rats, a single oral dose of 5 mmol diacetyl/kg bw (430 mg diacetyl/kg bw) was metabolised by reduction to acetoin, which was present in high concentrations of major organs one hour after dosing. The subsequent reduction product, butane-2,3-diol, was detected in the liver, kidney and brain. Only 10 minutes incubation time was required to convert 10 nmol (9 x 10 -4 mg) diacetyl to 3.7 nmol (3 x 10 -4 mg) acetoin and 6.3 nmol (6 x 10 -4 mg) butane-2,3-diol in rat liver homogenate (Otsuka et al., 1996) . The organ-specific reductase activity was greatest in the liver and least in the brain (Otsuka et al., 1996) .
Diacetyl and acetoin are reported to be formed endogenously in cats when pyruvate is converted to diacetyl and acetoin by pyruvate decarboxylase (Gabriel et al., 1972) . Mean fasting blood acetoin levels of approximately 100 microgram acetoin/100 ml blood have been reported (Dawson & Hullin, 1954) . Pyruvate also forms diacetyl in vitro in rat liver preparations (Järnefelt, 1955) and in microorganisms (Juni & Heym, 1956 (Frantz et al., 1998) . At lower dose levels oxidation predominates, whereas at the high dose urinary hydroxylated metabolites formed by hydroxylation and ketone reduction predominate. These mechanisms are similar to those observed for diacetyl.
III.4. Conclusions for Metabolism
It is anticipated that humans will metabolise aliphatic acyclic methyl ketones principally by oxidation of the terminal methyl group at low levels of exposure. At higher levels, reduction to the diol and subsequent conjugation with glucuronic acid is a competing detoxification pathway. Other aliphatic acyclic alpha-diketones and alpha-hydroxyketones are reduced, conjugated with glucuronic acid and excreted.
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The EFSA Journal (2008) 493, 36-48 Subacute / subchronic / chronic / Carcinogenic toxicity data are available for one candidate substance of the present FGE from chemical group 10, for three supporting substances evaluated by JECFA at the 51 th meeting and for one structurally related compound (pentan-2,4-dione). The supporting substances are listed in brackets. 2 Animals dosed ten times in fourteen days. 3 The study was performed at a single dose level or multiple dose levels that produced no adverse effects.
The EFSA Journal (2008) 493, 37-48 4 Animals dosed twice per day over a 126 day period at doses ranging from 100 to 250 mg/kg/day; animals that died or were killed during the study due to poor condition were replaced. 5 NOAEL for the central nervous system was determined to be <200 mg/kg/day. The NOAEL for thymus toxicity was determined to be 200 mg/kg/day. 6 One rabbit (50% of the group population) died due to possible aspiration of the test substance.
The EFSA Journal (2008) Unpublished valid study carried out according to EPA standards.
Only summarised results of the study available. Due to the lack of an effect on the PCE/NCE ratio it is unclear whether the test substance has reached the bone marrow. Relevance of the results is limited. 1 Excessive mortality was observed at 400 and 650 mg/kg dose levels; therefore, these dose levels were replaced with 50 and 100 mg/kg. 2 was tested in an in vivo Mouse Micronucleus Assay. Swiss Webster Mice (5 animals per sex/dose group) were given i.p. injections of 200, 400 and 650 mg/kg. Peripheral blood was sampled at 30, 48 and 72 hours post injection. Results: In a dose-finding study using 579-1200 mg/kg toxicity was observed from 694-1200 mg/kg (20% to 100% mortality) and an LD50 of 808 mg/kg i.p. was found (95% confidential interval 731.6-889.9 mg/ml). In this study, at 48 hrs post-injection, PCE/NCE ratio was reduced by 30% and 23% below the control levels for male and female animals that received a dose of 694 mg/kg, respectively.In the micronucleus study, the PCE/NCE ratio was determined in the 650 mg/kg group and in controls. No significant or dose-related decrease in the PCE/NCE ratio for either sex at any of the sample times (slight decrease with dose-related trend seen in females at 30hrs). In contrast, PCE/NCE ratio at 30 hrs was increased over control values in males at 400 and 650 mg/kg. A similar effect was not observed at any concentration at 48 hrs. A significant decrease in the PCE/NCE ratio (56.5% of the control) was observed with the positive control. The mean percentages of micronucleated PCEs were 0.38 and 0.22 for the vehicle control males and 0.12 and 0.14 for the vehicle control females sampled at 30 and 48 hrs, respectively. Mean percentages of micronucleated PCEs in CP-treated positive controls were 2.36 in males and 2.52 in females at 30 hrs post-treatment.At 30 hrs, a statistically significant increase in the incidence of micronucleated PCE was observed in the peripheral blood at 400 and 650 mg/kg. The effect was not dose-related. The mean percentages of micronucleated PCEs were 1.42 and 0.80 at 400 mg/kg and 1.16 and 0.80 at 650 mg/kg in males and females, respectively. At 48 hours a lower increase in micronucleated PCE than at 30 hrs was found at all concentrations tested. As there was no sex-related difference in the micronucleus response between males and females sampled at 48 and 72 hrs post-treatment, male and female values were combined for statistical analysis. A dose-related and statistically significant (p<0.001) increase in the incidence of micronuclei was observed at the 48 hrs sample period. A maximum incidence of 0.69% (3.8 times the vehicle controls) micronucleated PCEs was observed for the highest dose level tested. The maximum ratio in the incidences of micronucleated PCEs compared to control was 6.7 (0.80 % at 400 mg/kg at 30 h in females compared to 0.12 % in control females). At 72 hrs the micronucleus response had returned to baseline levels. 3 Pentan-2,4-dione (purity >98%) was tested in an in vivo Mouse Micronucleus Assay. Swiss Webster Mice (5 animals per sex/dose group) were given i.p injections of 400 and 650 mg/kg. Bone marrow was sampled 6, 24 and 48 hours post-injection. Results: Serious signs of toxicity were observed in both males and females at 650 mg/kg. Hypoactivity was seen in several males and females at 400 mg/kg. No serious signs of toxicity were observed in animals of either sex after day 1. In the micronucleus study, at 6 and 24 hrs a significant (p<0.05) increase in the PCE/NCE ratio over control values was observed at 400 mg/kg in males. No changes in the PCE/NCE ratio was seen in males at 48 hrs in either treatment group and in females of either treatment group at any sampling time. The mean percentages of micronucleated PCEs were 0.19, 0.29 and 0.18 for the vehicle control males and 0.20, 0.22 and 0.31 for the vehicle control females sampled at 6, 24 and 48 hrs, respectively. At 24 hrs the incidence of micronucleated PCEs was significantly increased in males and females at 400 and 650 mg/kg. The effect was not dose-related. The mean percentages of micronucleated PCEs were 0.81 and 0.97 at 400 mg/kg and 1.32 and 0.80 at 650 mg/kg in males and females, respectively. Mean percentages of micronucleated PCEs in CP-treated positive controls at 24 hrs post-treatment were 1.47 and 1.63% in males and females, respectively. The frequency of micronucleated PCEs was significantly increased at 24 hrs at 400 mg/kg and at 650 mg/kg, both in males and females. A maximum incidence of 1.32% (4.6 times the vehicle controls) micronucleated PCEs was observed for the highest dose level tested. This was also the maximum ratio in the incidences of micronucleated PCEs compared to control (1.32 % at 650 mg/kg at 24 h in males compared to 0.29 % in control males) . No significant increase of micronucleated PCEs was observed at 6 and 48 hrs at 400 mg/kg and at 650 mg/kg in either sex.
